TERC and Fanconi anemia: At our single institution, we had a yield of 14% (6/43) for patients with MDS or AML who were found to have a PV predisposing to myeloid disease (Fanconi Anemia, DKC1, DDX41, GATA2, TERC, and RUNX1).